# Personalis, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Personalis, Inc.). ## Overview Personalis, Inc. develops and sells advanced cancer genomic testing services for precision oncology and research applications. The company serves physicians, pharmaceutical and biopharmaceutical companies, diagnostics firms, universities, non-profits, and government customers from its CLIA-certified, CAP-accredited laboratory in Fremont, California. ## Products & services • NeXT Personal® Dx cancer testing • Advanced tumor genomic profiling services • MRD and recurrence monitoring tests • Whole exome sequencing services • Whole genome sequencing services • Genomic data analytics for research and trials - **Clinical diagnostic testing** (20%) — Tumor-informed and other cancer tests used by physicians to guide care and monitor recurrence. - **Pharma tests and services** (45%) — Testing and analytics for pharmaceutical oncology programs, translational research, and clinical trials. - **Enterprise sales** (15%) — Tumor profiling and diagnostic inputs sold to other businesses, including Natera-related services. - **Population sequencing** (18%) — Large-scale sequencing services supporting population genetics and research initiatives. - **Other research services** (2%) — Genomic tests and analytics sold to universities and non-profit research customers. - NeXT Personal® Dx cancer testing - Advanced tumor genomic profiling services - MRD and recurrence monitoring tests - Whole exome sequencing services - Whole genome sequencing services - Genomic data analytics for research and trials ## Customers Personalis sells to both clinical and research customers, with a large share of revenue tied to a small number of pharmaceutical and healthcare partners. Its end markets include oncology drug developers, healthcare providers treating cancer patients, diagnostics companies, and public-sector or academic research programs. - **Pharmaceutical and biopharmaceutical companies** (primary) — They buy testing services and analytics for translational research, biomarker discovery, and clinical trials. - **Clinical diagnostics / physicians** (primary) — They order NeXT Personal Dx and related cancer tests to detect residual or recurrent disease and support therapy selection. - **Diagnostics companies** (secondary) — They purchase whole exome sequencing and tumor analysis services as inputs to their own diagnostic offerings. - **Government and population sequencing programs** (secondary) — They use whole genome sequencing and analytics for large-scale genetic research initiatives. - **Universities and non-profits** (emerging) — They buy genomic testing and analytics for academic and non-commercial research projects. - Pharmaceutical companies buy testing for oncology trials and biomarker work - Physicians order cancer tests to detect recurrence and guide therapy - Diagnostics companies buy sequencing inputs for their own products - Government and population studies use large-scale sequencing services - Universities and non-profits buy genomic tests for research projects ## Geography Personalis derives most of its revenue in the United States, with smaller contributions from Europe, including the U.K., and a limited amount from the rest of the world, including Asia-Pacific. The company performs its laboratory work in Fremont, California, which anchors its operating footprint and regulatory compliance model. - **United States** (90%) — Principal market for testing services - **Europe (including the U.K.)** (9%) — Reported regional revenue share - **Rest of world, including Asia-Pacific** (1%) — Reported regional revenue share - United States is the main revenue market and operating base - Europe, including the U.K., is a smaller but established market - Asia-Pacific and other regions contribute a limited share of revenue - Fremont, California houses the CLIA and CAP-accredited laboratory - Geographic sales coverage is organized through a small direct sales force ## Strategy Personalis is focused on expanding adoption of its NeXT Personal testing platform in clinical diagnostics while continuing to serve pharma and research customers. The company is also building clinical evidence, reimbursement support, and commercial partnerships to broaden access to its tests and reduce reliance on a small number of large accounts. - **Expand clinical diagnostics commercialization** (short-term) — Clinical adoption can create a broader, more recurring customer base than project-based research work. - **Build reimbursement and clinical evidence** (medium-term) — Coverage and published evidence support physician adoption and payer reimbursement. - **Diversify customer concentration** (medium-term) — Reducing dependence on a few large customers lowers volatility from trial timing and renewals. - Expand NeXT Personal Dx capacity to support clinical demand - Use Tempus partnership to broaden commercial reach - Build clinical evidence and reimbursement coverage - Grow pharma and biotech sales for trial and research use - Diversify revenue beyond a few large customers ## Risks Personalis faces customer concentration risk because a small number of large accounts can drive a substantial share of revenue, and those customers' trial timing can be volatile. The business also depends on reimbursement, regulatory compliance, and data security, which are especially important in genomic testing because the company handles sensitive patient and genomic information. - **Customer concentration** [high] — A few customers account for a large share of revenue, so renewals or project changes can materially affect results. - **Clinical trial and project timing** [high] — Pharma and research revenue depends on the start, pace, and completion of external studies. - **Reimbursement and coverage risk** [medium] — Clinical diagnostics depend on Medicare and private payer coverage for adoption and volume growth. - **Cybersecurity and sensitive data protection** [high] — The company processes PHI, genomic data, and financial information, increasing breach and compliance risk. - **Sustained losses** [medium] — The company has a history of losses and may need continued capital to support growth and operations. - Revenue concentration creates volatility if large customers reduce orders - Clinical trial timing can shift revenue from quarter to quarter - Reimbursement uncertainty can limit clinical test adoption - Cybersecurity and PHI exposure create regulatory and reputational risk - Losses and funding needs remain a structural risk for the business ## Accounting The most important accounting judgments are revenue recognition, leases, and common stock warrants. Revenue can vary with the timing of clinical trials, customer projects, and reimbursements, while lease and warrant valuations can materially affect reported assets, liabilities, and earnings. - **Revenue recognition** — Can shift revenue between quarters and affect comparability - **Leases** — Affects right-of-use assets, lease liabilities, and expense timing - **Common stock warrants** — Can materially affect other income/expense and equity - **Allowance for credit losses / collectability** — Can affect bad debt expense and working capital - Revenue recognition depends on project timing and service delivery - Clinical diagnostic revenue is affected by payer reimbursement timing - Leases are material because of the Fremont headquarters and lab footprint - Warrant accounting can affect fair value gains or losses - Customer concentration increases collectability and reserve judgment --- *Last updated: 2026-04-29T04:48:26.366057+00:00*